Caladrius Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CLBS and buy or sell other stocks, ETFs, and their options commission-free!About CLBS
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors.
CEODavid J. Mazzo, PhD
CEODavid J. Mazzo, PhD
Employees26
Employees26
HeadquartersBasking Ridge, New Jersey
HeadquartersBasking Ridge, New Jersey
Founded1980
Founded1980
Employees26
Employees26
CLBS Key Statistics
Market cap23.29M
Market cap23.29M
Price-Earnings ratio-0.96
Price-Earnings ratio-0.96
Dividend yield—
Dividend yield—
Average volume22.65K
Average volume22.65K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.20
52 Week high$4.20
52 Week low$1.81
52 Week low$1.81
Stock Snapshot
With a market cap of 23.29M, Caladrius Biosciences(CLBS) trades at $2.66. The stock has a price-to-earnings ratio of -0.96.
On 2025-12-12, Caladrius Biosciences(CLBS) stock opened at —, reached a high of —, and a low of —.
The Caladrius Biosciences(CLBS)'s current trading volume is 0, compared to an average daily volume of 22.65K.
During the past year, Caladrius Biosciences(CLBS) stock moved between $1.81 at its lowest and $4.20 at its peak.
During the past year, Caladrius Biosciences(CLBS) stock moved between $1.81 at its lowest and $4.20 at its peak.
People also own
Based on the portfolios of people who own CLBS. This list is generated using Robinhood data, and it’s not a recommendation.